Pegfilgrastim, a long-acting granulocyte-colony stimulating factor (G-CSF) therapy, has become a key product for the prophylaxis and treatment of febrile neutropenia, and biosimilar options have the potential to reduce the high cost of pegfilgrastim therapy. At the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, 2 research teams presented on studies assessing proposed pegfilgrastim biosimilar products.
Pegfilgrastim, a long-acting granulocyte-colony stimulating factor (G-CSF) therapy, has become vital for the prophylaxis and treatment of febrile neutropenia, and biosimilar options have the potential to reduce the high cost of this treatment. At the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, 2 research teams presented on studies assessing proposed pegfilgrastim biosimilar products.
Bone Pain Is Similar in Those Receiving Biosimilar or Reference Pegfilgrastim
Bone pain is a frequent adverse event (AE) associated with the use of G-CSF therapies, including pegfilgrastim. Among patients who receive pegfilgrastim, bone pain has previously been shown to occur in approximately 25% to 38% (while among healthy volunteers, 52% to 84% experience bone pain).
Nadia Harbeck, MD, PhD, reported on her team’s assessment of bone pain in a phase 1 study of Sandoz’s proposed pegfilgrastim biosimilar in healthy volunteers, as well as 2 randomized phase 3 confirmatory studies conducted in patients with breast cancer who were undergoing chemotherapy for up to 6 cycles.1 The phase 3 studies compared the proposed biosimilar to the reference pegfilgrastim.
In the phase 1 study, bone pain was reported by 58% of healthy volunteers receiving the biosimilar and 53% of those receiving the reference. In the 2 phase 3 trials, bone pain was reported by 4.4% and 4.5% of those receiving the biosimilar and 5.1% and 8.5% of those receiving the reference.
Harbeck and colleagues concluded that bone pain was similar with the proposed biosimilar and its reference in these studies.
Switching From Reference to RGB-02 Is Safe and Effective
A research team from Gedeon Richter also presented on multiple studies of a proposed pegfilgrastim biosimilar, RGB-02.2
The team analyzed the results from 2 pharmacokinetic (PK)/pharmacodynamic (PD) studies in healthy volunteers and a comparative efficacy and safety study in patients receiving chemotherapy. The PK/PD studies had a cross-over design, and endpoints related to changes in absolute neutrophil count were assessed. Patients in the comparative study switched from the reference to the biosimilar after 2 cycles of chemotherapy.
The researchers found that none of the PD endpoints showed any difference following crossover in the PK/PD studies, and in the patients who switched to the biosimilar, the mean duration of severe neutropenia was similar to values prior to the switch. The switch did not result in decreased efficacy versus continuous treatment with the biosimilar.
Treatment with the reference can be safely switched to the biosimilar without impacting therapeutic effect, the researchers concluded.
References
1. Harbeck N, et al. Safety analysis of proposed biosimilar pegfilgrastim in phase I and phase III studies. Presented at the European Society for Medical Oncology 2018 Congress, October 19-23, 2018; Munich, Germany. Abstract 169P. https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/session/calendar?q=1698P&c=abs.
2. Illes A, et al. Safe switch of treatment from the reference product to RGB-02, a proposedbiosimilar pegfilgrastim: analysis of the results of three clinical trials. Presented at the European Society for Medical Oncology 2018 Congress, October 19-23, 2018; Munich, Germany. Abstract 1700P. https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/session/calendar?q=1698P&c=abs.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.